Titre | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy |
Protocole ID | DEBIO-1143-SCCHN-301 (TrilynX) |
ClinicalTrials.gov ID | NCT04459715 |
Type(s) de cancer | ORL |
Phase | Phase III |
Type étude | Clinique |
Médicament | Xevinapant |
Institution |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Ville | Montréal |
Investigateur(trice) principal(e) |
Dr Denis Soulières |
Coordonnateur(trice) |
Anick Lambert 514-890-8000 poste 23195 Francine Richard 514-890-8000 poste 24853 |
Statut | Fermé |
Critètes d'éligibilité |
Les plus pertinents
|
Critètes d'exclusion |
Les plus pertinents
|